Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Upstream Bio (UPB) Receivables (2023 - 2025)

Upstream Bio (UPB) has 3 years of Receivables data on record, last reported at $2.3 million in Q3 2025.

  • For Q3 2025, Receivables rose 111.26% year-over-year to $2.3 million; the TTM value through Sep 2025 reached $2.3 million, up 111.26%, while the annual FY2024 figure was $1.2 million, 400.0% up from the prior year.
  • Receivables reached $2.3 million in Q3 2025 per UPB's latest filing, down from $2.6 million in the prior quarter.
  • Across five years, Receivables topped out at $2.6 million in Q2 2025 and bottomed at $236000.0 in Q4 2023.
  • Average Receivables over 3 years is $1.4 million, with a median of $1.2 million recorded in 2024.
  • Peak YoY movement for Receivables: soared 400.0% in 2024, then soared 111.26% in 2025.
  • A 3-year view of Receivables shows it stood at $236000.0 in 2023, then skyrocketed by 400.0% to $1.2 million in 2024, then surged by 95.51% to $2.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $2.3 million in Q3 2025, $2.6 million in Q2 2025, and $1.7 million in Q1 2025.